Minkwan Cho, Eunkyung Park, Yong-Pyo Lee, Hongsik Kim, Hee Sue Park, Hee Kyung Kim, Yaewon Yang, Jihyun Kwon, Ki Hyeong Lee, Hye Sook Han
{"title":"食管胃癌或胰胆管癌患者化疗所致贫血的羧甲基亚铁或达贝泊汀α疗效：一项回顾性比较研究。","authors":"Minkwan Cho, Eunkyung Park, Yong-Pyo Lee, Hongsik Kim, Hee Sue Park, Hee Kyung Kim, Yaewon Yang, Jihyun Kwon, Ki Hyeong Lee, Hye Sook Han","doi":"10.1177/17588359241265209","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Esophagogastric and pancreaticobiliary cancers are associated with chronic blood loss, poor nutrition, and surgical interventions that interfere with iron absorption. Patients with these cancers often have a higher incidence of chemotherapy-induced anemia (CIA) than patients with other malignancies.</p><p><strong>Objectives: </strong>To investigate the efficacy of intravenous iron or erythropoietin-stimulating agents (ESA) for CIA treatment in patients with esophagogastric or pancreaticobiliary cancer.</p><p><strong>Design: </strong>Retrospective, comparative chart review of patients with esophagogastric or pancreaticobiliary cancer who received ferric carboxymaltose (FCM), or darbepoetin alfa (DA), and myelosuppressive chemotherapy at Chungbuk National University Hospital between June 2018 and December 2022.</p><p><strong>Methods: </strong>To assess the efficacy of FCM or DA over time, data on hemoglobin (Hb) levels were collected from the time of administration of FCM or DA (baseline) until 6 months post-baseline, when available.</p><p><strong>Results: </strong>In total, 214 patients (124 in the FCM and 90 in the DA group) were included in the analysis. The FCM group had a higher maximum Hb level and Hb changes for 3 months (mean ± standard deviation) following FCM or DA administration from baseline than the DA group (11.3 ± 1.5 <i>versus</i> 10.9 ± 1.2 g/dL, <i>p</i> = 0.02 and 2.0 ± 1.4 <i>versus</i> 1.5 ± 1.1 g/dL, <i>p</i> = 0.004, respectively). The FCM group had a higher proportion of Hb responders than the DA group (83.9% <i>versus</i> 68.9%, <i>p</i> = 0.013). Based on multivariable analysis, only the CIA treatment group was a significant factor for Hb response (odds ratio = 2.06, 95% confidence interval = 1.05-4.06, <i>p</i> = 0.036).</p><p><strong>Conclusion: </strong>Both FCM and DA are effective, and FCM showed a higher Hb response than DA for CIA treatment in patients with esophagogastric or pancreaticobiliary cancer. Therefore, further randomized controlled trials should determine the optimal treatment for CIA in patients with these cancers undergoing myelosuppressive chemotherapy.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"16 ","pages":"17588359241265209"},"PeriodicalIF":4.3000,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11292682/pdf/","citationCount":"0","resultStr":"{\"title\":\"Efficacy of ferric carboxymaltose or darbepoetin alfa for chemotherapy-induced anemia in patients with esophagogastric or pancreaticobiliary cancer: a retrospective comparative study.\",\"authors\":\"Minkwan Cho, Eunkyung Park, Yong-Pyo Lee, Hongsik Kim, Hee Sue Park, Hee Kyung Kim, Yaewon Yang, Jihyun Kwon, Ki Hyeong Lee, Hye Sook Han\",\"doi\":\"10.1177/17588359241265209\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Esophagogastric and pancreaticobiliary cancers are associated with chronic blood loss, poor nutrition, and surgical interventions that interfere with iron absorption. Patients with these cancers often have a higher incidence of chemotherapy-induced anemia (CIA) than patients with other malignancies.</p><p><strong>Objectives: </strong>To investigate the efficacy of intravenous iron or erythropoietin-stimulating agents (ESA) for CIA treatment in patients with esophagogastric or pancreaticobiliary cancer.</p><p><strong>Design: </strong>Retrospective, comparative chart review of patients with esophagogastric or pancreaticobiliary cancer who received ferric carboxymaltose (FCM), or darbepoetin alfa (DA), and myelosuppressive chemotherapy at Chungbuk National University Hospital between June 2018 and December 2022.</p><p><strong>Methods: </strong>To assess the efficacy of FCM or DA over time, data on hemoglobin (Hb) levels were collected from the time of administration of FCM or DA (baseline) until 6 months post-baseline, when available.</p><p><strong>Results: </strong>In total, 214 patients (124 in the FCM and 90 in the DA group) were included in the analysis. The FCM group had a higher maximum Hb level and Hb changes for 3 months (mean ± standard deviation) following FCM or DA administration from baseline than the DA group (11.3 ± 1.5 <i>versus</i> 10.9 ± 1.2 g/dL, <i>p</i> = 0.02 and 2.0 ± 1.4 <i>versus</i> 1.5 ± 1.1 g/dL, <i>p</i> = 0.004, respectively). The FCM group had a higher proportion of Hb responders than the DA group (83.9% <i>versus</i> 68.9%, <i>p</i> = 0.013). Based on multivariable analysis, only the CIA treatment group was a significant factor for Hb response (odds ratio = 2.06, 95% confidence interval = 1.05-4.06, <i>p</i> = 0.036).</p><p><strong>Conclusion: </strong>Both FCM and DA are effective, and FCM showed a higher Hb response than DA for CIA treatment in patients with esophagogastric or pancreaticobiliary cancer. Therefore, further randomized controlled trials should determine the optimal treatment for CIA in patients with these cancers undergoing myelosuppressive chemotherapy.</p>\",\"PeriodicalId\":23053,\"journal\":{\"name\":\"Therapeutic Advances in Medical Oncology\",\"volume\":\"16 \",\"pages\":\"17588359241265209\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11292682/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Medical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/17588359241265209\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Medical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17588359241265209","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：食管胃癌和胰胆管癌与长期失血、营养不良以及影响铁吸收的手术干预有关。与其他恶性肿瘤患者相比，这些癌症患者的化疗诱发性贫血（CIA）发生率往往更高：研究静脉注射铁剂或促红细胞生成素（ESA）治疗食管胃癌或胰胆管癌患者 CIA 的疗效：对2018年6月至2022年12月期间在忠北国立大学医院接受羧甲基亚铁（FCM）或达贝泊汀α（DA）和骨髓抑制性化疗的食管胃癌或胰胆管癌患者进行回顾性、比较性病历审查：为评估FCM或DA随时间推移的疗效，收集了从服用FCM或DA时（基线）到基线后6个月的血红蛋白（Hb）水平数据（如有）：共有 214 名患者（124 名 FCM 组和 90 名 DA 组）被纳入分析。与 DA 组相比，FCM 组的最大 Hb 水平更高，从基线开始服用 FCM 或 DA 后 3 个月的 Hb 变化（平均值 ± 标准差）也更大（分别为 11.3 ± 1.5 对 10.9 ± 1.2 g/dL，p = 0.02 和 2.0 ± 1.4 对 1.5 ± 1.1 g/dL，p = 0.004）。FCM 组的血红蛋白应答者比例高于 DA 组（83.9% 对 68.9%，p = 0.013）。根据多变量分析，只有 CIA 治疗组是影响 Hb 反应的重要因素（几率比 = 2.06，95% 置信区间 = 1.05-4.06，p = 0.036）：结论：FCM 和 DA 均有效，在食管胃癌或胰胆管癌患者的 CIA 治疗中，FCM 比 DA 显示出更高的 Hb 反应。因此，应进一步开展随机对照试验，以确定对接受骨髓抑制性化疗的这些癌症患者进行 CIA 治疗的最佳方法。
Efficacy of ferric carboxymaltose or darbepoetin alfa for chemotherapy-induced anemia in patients with esophagogastric or pancreaticobiliary cancer: a retrospective comparative study.
Background: Esophagogastric and pancreaticobiliary cancers are associated with chronic blood loss, poor nutrition, and surgical interventions that interfere with iron absorption. Patients with these cancers often have a higher incidence of chemotherapy-induced anemia (CIA) than patients with other malignancies.
Objectives: To investigate the efficacy of intravenous iron or erythropoietin-stimulating agents (ESA) for CIA treatment in patients with esophagogastric or pancreaticobiliary cancer.
Design: Retrospective, comparative chart review of patients with esophagogastric or pancreaticobiliary cancer who received ferric carboxymaltose (FCM), or darbepoetin alfa (DA), and myelosuppressive chemotherapy at Chungbuk National University Hospital between June 2018 and December 2022.
Methods: To assess the efficacy of FCM or DA over time, data on hemoglobin (Hb) levels were collected from the time of administration of FCM or DA (baseline) until 6 months post-baseline, when available.
Results: In total, 214 patients (124 in the FCM and 90 in the DA group) were included in the analysis. The FCM group had a higher maximum Hb level and Hb changes for 3 months (mean ± standard deviation) following FCM or DA administration from baseline than the DA group (11.3 ± 1.5 versus 10.9 ± 1.2 g/dL, p = 0.02 and 2.0 ± 1.4 versus 1.5 ± 1.1 g/dL, p = 0.004, respectively). The FCM group had a higher proportion of Hb responders than the DA group (83.9% versus 68.9%, p = 0.013). Based on multivariable analysis, only the CIA treatment group was a significant factor for Hb response (odds ratio = 2.06, 95% confidence interval = 1.05-4.06, p = 0.036).
Conclusion: Both FCM and DA are effective, and FCM showed a higher Hb response than DA for CIA treatment in patients with esophagogastric or pancreaticobiliary cancer. Therefore, further randomized controlled trials should determine the optimal treatment for CIA in patients with these cancers undergoing myelosuppressive chemotherapy.
期刊介绍：
Therapeutic Advances in Medical Oncology is an open access, peer-reviewed journal delivering the highest quality articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of cancer. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in medical oncology, providing a forum in print and online for publishing the highest quality articles in this area. This journal is a member of the Committee on Publication Ethics (COPE).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
